Millicent Grace Alison Bennett

Ms. Millicent Grace Alison Bennett

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMillicent Grace Alison Bennett
Millicent Grace Alison Bennett
AMAshley Meakin
Ashley Meakin
KBKimberley J. Botting-Lawford
Kimberley J. Botting-Lawford
YNYouguo Niu
Youguo Niu
SFSage G Ford
Sage G Ford
JMJanna Morrison
Janna Morrison
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.

1 April 2020 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
MBMillicent Grace Alison Bennett
Millicent Grace Alison Bennett
RVR. Vivancos-Koopman
R. Vivancos-Koopman
LSL.A. Seewald
L.A. Seewald
TRT. Robinette
T. Robinette
MDM.L. Delco
M.L. Delco

27 October 2025 in Biochemical Pharmacology
Verified
Journal Article
Open access
MBMillicent Grace Alison Bennett
Millicent Grace Alison Bennett
AMAshley S. Meakin
Ashley S. Meakin
KBKimberley J. Botting-Lawford
Kimberley J. Botting-Lawford
YNYouguo Niu
Youguo Niu
SFSage G. Ford
Sage G. Ford
JMJanna Morrison
Janna Morrison
Fetal hypoxaemia promotes oxidative stress and increases risk of chronic diseases in later life. The medications for managing chronic diseases are often metabolised by hepatic cytochrome P450 (CYP) enzymes; however, it is unknown if oxidative stress in utero programs altered CYP activity. Maternal treatment with the antioxidant MitoQ protects against hypertension in adult offspring, programmed by fetal hypoxaemia. We hypothesised that fetal hypoxaemia alters offspring CYP activity and MitoQ would rescue this. From 105-138 days gestational age (dGA), ewes carrying singletons were randomly allocated to normoxic (n = 34, 21 % O2) or hypoxic (n = 36, 11 % O2) pregnancy with maternal vehicle (n = 34) or MitoQ (n = 36, 6 mg kg-1 MS010 IV) daily bolus. Male fetuses were humanely killed at 137 ± 2 dGA while female fetuses lambed spontaneously and were humanely killed at 9 months of age (9mo). Hepatic CYP activity and protein abundance were quantified using functional assays and Western blot. Hypoxic pregnancy increased fetal ATF-6 expression, decreased 9mo CYP2B6 and CYP2E1 activity, and decreased mitochondrial abundance at 9mo. MitoQ decreased fetal CYP3A activity, while at 9mo CYP3A activity increased and CYP1A2 activity decreased. MitoQ decreased fetal mitochondrial abundance and expression of mitochondrial complexes I and IV, but at 9mo complex II and IV expression increased. MitoQ also increased fetal and 9mo ATF-6 expression and 9mo HNF-4ɑ and PPARɑ expression. Fetal hypoxaemia and maternal MitoQ treatment independently programmed hepatic CYP activity in fetal sheep and 9mo lambs. These effects may impact therapeutic efficacy and safety for treatment of chronic diseases in offspring from complicated pregnancies.

13 August 2026 in Pharmacological Research
Verified
Journal Article
Open access
MBMillicent Grace Alison Bennett
Millicent Grace Alison Bennett
AMAshley S. Meakin
Ashley S. Meakin
KBKimberley J. Botting-Lawford
Kimberley J. Botting-Lawford
YNYouguo Niu
Youguo Niu
SFSage G. Ford
Sage G. Ford
JMJanna Morrison
Janna Morrison